Most Read

This marketing authorisation is applicable for use of Kapruvia in all member states of the European Union besides Iceland, Liechtenstein and Norway. The approval comes after the US

An orally disintegrating tablet and a calcitonin gene-related peptide (CGRP) receptor antagonist, Vydrua got the marketing authorisation for acute treatment of migraine with or without aura, and prophylaxis

This treatment is meant for patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer patients who have earlier received a systemic therapy in

The move supports the indication of a single priming anti-CTLA4 antibody dose added to the human monoclonal antibody Imfinzi (durvalumab) to treat HCC patients. AstraZeneca also submitted a

The drug will be indicated as an adjuvant treatment for NSCLC in adults with a high risk of recurrence with PD-L1≥50% and without EGFR mutant or ALK-positive NSCLC,

Although HCC is the most common type of liver cancer, options to treat the disease are restricted. The total prognosis for survival is poor, with a five-year survival

BenevolentAI is clinical-stage artificial intelligence (AI) enabled drug discovery company, while DNDi) is a not-for-profit research and development (R&D) organisation with focus on neglected diseases., The company focuses

Located in Frederick, Maryland, the 275,000ft2 facility will produce the FDA-approved CAR T-cell therapy which is utilised for the treatment of blood cancer. The CAR T-cell therapies are

As part of the collaboration, the companies will jointly develop new antibody drugs which can significantly expand the immunotherapy’s potential in improving the lives of cancer and other